Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhijian LiangHWHua Wang

Discussion

Loading...

Member takes

Overview

Phase I trial shows 100% overall response in newly diagnosed high-risk multiple myeloma patients with manageable safety.

Key Points

  • To evaluate the safety and efficacy of selinexor combined with standard myeloma therapies in high-risk patients.
  • Conducted a multi-center, single-arm phase Ib/II trial
  • Patients received selinexor, bortezomib, lenalidomide, and dexamethasone for induction therapy
  • Assessed safety/tolerability, RP2D, overall response rate, and minimal residual disease negativity after treatment.
  • Achieved a 100% overall response rate in evaluable patients
  • Reported a complete response rate of 50% and minimal residual disease negativity rate of 75% after induction
  • Identified manageable grade 3/4 treatment-related adverse events including thrombocytopenia and neutropenia.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d175https://doi.org/10.1182/blood-2025-5829
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial2026 · 2 citations
  2. 2Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study2025
  3. 3The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma2025
  4. 4Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)2025 · 3 citations
  5. 5A novel conditioning regimen combining selinexor with melphalan Improves Survival in Patients with multiple myeloma:a prospective study2025